CD9 and prostate cancer: Transfection of miR-4289 mimic, had no significant effect on CD9 total protein levels in RWPE1 cells at 72h (106%, p = 0.6018), or DU145 prostate cancer cells at 72h (75.8%, p = 0.1102) and so was not assessed further (Figure 5).